Cryoballoon Pulmonary Vein Isolation for Atrial Fibrillation With Heart Failure

Brief summary (registry, in English)

The combination of atrial fibrillation (AF) and heart failure (HF) is common and implies a poor prognosis. Pulmonary vein isolation is an established method for the treatment of symptomatic AF in patients with normal heart function and has been shown to be more effective than drug therapy. Recently, radiofrequency ablation has shown a positive effect in patients with AF and HF. POLAR-HF has been designed to investigate efficacy and safety of cryoballoon pulmonary vein isolation in patients with paroxysmal or persistent AF and severe HF (LVEF ≤ 40%).

What you commit to

• Study type: Interventional
• Participants enrolled: 1420
• From 1 Jan 2018 to the primary completion date, 31 Jan 2025
• 1 site in 1 country
• Visits and tests: ask the trial team, the registry does not list them

Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.

Who cannot take part

Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.

Who the study is looking for

Age in the registry: 18 years to 99 years · Sex: All · Does not accept healthy volunteers

Full criteria on ClinicalTrials.gov

Sites (1)

Sites in registry order. Pick your city on the disease page to sort them by distance.

Related publications

• Pulmonary Vein Isolation Only for Atrial Fibrillation With Heart Failure (POLAR-HF).JACC Clin Electrophysiol · 2026 · PMID 41263723